Senate Committee Looks at 340B
Last week the Senate Committee on Health, Education, Labor and Pensions held a hearing on the 340B Drug Pricing Program to discuss its growth and impact on patients. Among other subjects, the committee reviewed the importance of the 340B program; the pharmaceutical manufacturers’ rebate program that begins in January; potential transparency reforms; ensuring that 340B entities do not receive duplicate drug discounts; revising the definition of a patient for a covered entity; and reforms involving the use of contract pharmacies. Representatives from the Government Accountability Office, Congressional Budget Office (CBO), UCLA served on the hearing’s witness panel. Go here to find [...]
